TY - JOUR
T1 - Determinants of health-related quality of life in pharmacoresistant epilepsy
T2 - Results from a large multicenter study of consecutively enrolled patients using validated quantitative assessments
AU - Luoni, Chiara
AU - Bisulli, Francesca
AU - Canevini, Maria Paola
AU - De Sarro, Giovambattista
AU - Fattore, Cinzia
AU - Galimberti, Carlo Andrea
AU - Gatti, Giuliana
AU - La Neve, Angela
AU - Muscas, Giancarlo
AU - Specchio, Luigi Maria
AU - Striano, Salvatore
AU - Perucca, Emilio
PY - 2011/12
Y1 - 2011/12
N2 - Purpose: To evaluate the relative contribution of demographic and epilepsy-related variables, depressive symptoms, and adverse effects (AEs) of antiepileptic drugs (AEDs) to health-related quality of life (HRQOL) in adults with pharmacoresistant epilepsy. Methods: Individuals with epilepsy whose seizures failed to respond to at least one AED were enrolled consecutively at 11 tertiary referral centers. HRQOL was assessed by the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), AEs by the Adverse Event Profile (AEP), and depressive symptoms by the Beck Depression Inventory-II (BDI-II). Multivariate linear regression models were used to identify variables associated with QOLIE-31 total score and subscale scores. Key Findings: Of 933 enrolled individuals aged 16 years or older, 809 (87%) were able to complete the self-assessment instruments and were included in the analysis. Overall, 61% of the variance in QOLIE-31 scores was explained by the final model. The strongest predictors of HRQOL were AEP total scores (β = -0.451, p <0.001) and BDI-II scores (β = -0.398, p <0.001). These factors were also the strongest predictors of scores in each of the seven QOLIE-31 subscales. Other predictors of HRQOL were age (β = -0.060, p = 0.008), lack of a driving license (β = -0.053, p = 0.018), pharmacoresistance grade, with higher HRQOL in individuals who had failed only one AED (β = 0.066, p = 0.004), and location of the enrolling center. Epilepsy-related variables (seizure frequency, occurrence of tonic-clonic seizures, age of epilepsy onset, disease duration) and number of AEDs had no significant predictive value on HRQOL. The AEP total score was the strongest negative predictor of HRQOL in the subgroup of 362 patients without depressive symptoms (BDI-II score
AB - Purpose: To evaluate the relative contribution of demographic and epilepsy-related variables, depressive symptoms, and adverse effects (AEs) of antiepileptic drugs (AEDs) to health-related quality of life (HRQOL) in adults with pharmacoresistant epilepsy. Methods: Individuals with epilepsy whose seizures failed to respond to at least one AED were enrolled consecutively at 11 tertiary referral centers. HRQOL was assessed by the Quality of Life in Epilepsy Inventory-31 (QOLIE-31), AEs by the Adverse Event Profile (AEP), and depressive symptoms by the Beck Depression Inventory-II (BDI-II). Multivariate linear regression models were used to identify variables associated with QOLIE-31 total score and subscale scores. Key Findings: Of 933 enrolled individuals aged 16 years or older, 809 (87%) were able to complete the self-assessment instruments and were included in the analysis. Overall, 61% of the variance in QOLIE-31 scores was explained by the final model. The strongest predictors of HRQOL were AEP total scores (β = -0.451, p <0.001) and BDI-II scores (β = -0.398, p <0.001). These factors were also the strongest predictors of scores in each of the seven QOLIE-31 subscales. Other predictors of HRQOL were age (β = -0.060, p = 0.008), lack of a driving license (β = -0.053, p = 0.018), pharmacoresistance grade, with higher HRQOL in individuals who had failed only one AED (β = 0.066, p = 0.004), and location of the enrolling center. Epilepsy-related variables (seizure frequency, occurrence of tonic-clonic seizures, age of epilepsy onset, disease duration) and number of AEDs had no significant predictive value on HRQOL. The AEP total score was the strongest negative predictor of HRQOL in the subgroup of 362 patients without depressive symptoms (BDI-II score
KW - Adverse event profile
KW - Antiepileptic drugs
KW - Depression
KW - Pharmacoresistance
UR - http://www.scopus.com/inward/record.url?scp=82955207124&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=82955207124&partnerID=8YFLogxK
U2 - 10.1111/j.1528-1167.2011.03325.x
DO - 10.1111/j.1528-1167.2011.03325.x
M3 - Article
C2 - 22136077
AN - SCOPUS:82955207124
VL - 52
SP - 2181
EP - 2191
JO - Epilepsia
JF - Epilepsia
SN - 0013-9580
IS - 12
ER -